In the last trading session, 1.58 million shares of the Gossamer Bio Inc (NASDAQ:GOSS) were traded, and its beta was 1.79. Most recently the company’s share price was $1.28, and it changed around -$0.11 or -7.91% from the last close, which brings the market valuation of the company to $290.84M. GOSS currently trades at a discount to its 52-week high of $1.55, offering almost -21.09% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has risen by an impressive 60.94% since then. We note from Gossamer Bio Inc’s average daily trading volume that its 10-day average is 1.64 million shares, with the 3-month average coming to 1.39 million.
Gossamer Bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended GOSS as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Gossamer Bio Inc is expected to report earnings per share of -0.19 for the current quarter.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Instantly GOSS has showed a red trend with a performance of -7.91% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.4400 on recent trading dayincreased the stock’s daily price by 11.11%. The company’s shares are currently up 41.50% year-to-date, but still down -7.91% over the last five days. On the other hand, Gossamer Bio Inc (NASDAQ:GOSS) is -8.57% down in the 30-day period. We can see from the shorts that 5.59 million shares have been sold at a short interest cover period of 3.23 day(s).
The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 68.0% from its current value. Analyst projections state that GOSS is forecast to be at a low of $2 and a high of $5.
Gossamer Bio Inc (GOSS) estimates and forecasts
The year-over-year growth rate is expected to be -82.69%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 3.95M in revenue for the current quarter. 8 analysts expect Gossamer Bio Inc to make 4.09M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at -95.73%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 40.29%. Gossamer Bio Inc earnings are expected to increase by -183.43% in 2025, but the outlook is positive 22.43% per year for the next five years.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.28% of Gossamer Bio Inc shares, and 76.50% of them are in the hands of institutional investors. The stock currently has a share float of 79.09%. Gossamer Bio Inc stock is held by 122.0 institutions, with NEA MANAGEMENT COMPANY, LLC being the largest institutional investor. By 2024-06-30, it held 7.9979% of the shares, which is about 18.09 million shares worth $16.3 million.
ARTAL GROUP S.A., with 5.8832% or 13.31 million shares worth $11.99 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Biotechnology Portfolio and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 7.91 shares worth $10.13 million, making up 3.48% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 6.76 shares worth around $8.66 million, which represents about 2.98% of the total shares outstanding.
